Phase 3 N=704 Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Melanoma
Primary: Overall Survival (OS) — 26.0; 17.8 Months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=322 GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma
Melanoma
Primary: Progression-free Survival in BRAF V600E Mutation-positive Participants Without a History of Brain Metastases as Assessed by the Investigator and Independent Review…
Phase 2 N=9 Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations
Recurrent Melanoma · Stage IIIB Melanoma · Stage IIIC Melanoma
Primary: Overall Response Rate in "High Affinity" Group — 0.5 Proportion of participants
Phase 1 N=46 A Study of Vemurafenib (Zelboraf) in Chinese Participants With BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma
Malignant Melanoma
Primary: Area Under the Plasma Concentration-Time Curve (AUC) of RO5185426 From 0 to 8 Hours on Day 1 — 37.54 h*μg/mL
Phase 2 N=146 A Study of Vemurafenib in Metastatic Melanoma Participants With Brain Metastases
Malignant Melanoma
Primary: Best Overall Response Rate (BORR) Within Brain of Previously Untreated Participants (Assessed by Independent Review Committee [IRC] Using Modified Response Evaluation…
Phase 2 N=8 BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma
BRAF Mutant Metastatic Melanoma
Primary: Phase 1 - Safety & Recommended Phase 2 Dose (RP2D) — 60 mg
Phase 2 N=172 A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma to the Brain
Melanoma and Brain Metastases
Primary: Number of Participants With BRAF V600E Mutation-positive Melanoma With Overall Intracranial Response (OIR), as Assessed by the Investigator — 4; 1; 26; 23 participants…
Phase 2 N=183 A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma
BRAF or NRAS Mutant Metastatic Melanoma
Primary: Percentage of Participants With Objective Response (OR) — 4.9; 14.5; 12.0 percentage of participants
Phase 2 N=92 A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma
Melanoma
Primary: Number of Participants With a Best Overall Response of Confirmed Complete Response (CR) or Partial Response (PR) as Assessed by the Investigator for Participants Who Had…
Phase 2 N=5 LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma
Melanoma
Primary: Dose Limiting Toxicity (DLT) [Phase I] — 1 Participants
Phase 2 N=208 A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers
Multiple Myeloma, Neoplasms
Primary: Confirmed Best Overall Response Rate (BORR) — 37.1; 50.0; 0; 7.4 percentage of participants
Phase 1 N=131 A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma
Malignant Melanoma
Primary: Number of Participants With Dose-Limiting Toxicities (DLTs) During DES in Combination Cohorts — 0; 0; 1; 0 participants
Phase 3 N=3,219 A Study of Vemurafenib in Participants With Metastatic Melanoma
Malignant Melanoma
Primary: Percentage of Participants Experiencing Any Grade 3 or 4 Adverse Events (AEs) as Determined by National Cancer Institute-Common Toxicity Criteria for Adverse Events…
Phase 2 N=7 BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation
Melanoma
Primary: Number of Participants With Response According to RECIST v1.1 Criteria — 2; 2; 2; 1 Participants
Phase 2 N=17 LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations
Stage III Melanoma · Stage IV Melanoma · Unresectable Melanoma
Primary: Change in Kinase Expression — -20.87259; -19.64376; -16.41738; -12.5401 Sum Log 2 Fold Change Kinase Expression
Phase 2 N=49 Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic
Recurrent Melanoma · Stage IIIA Melanoma · Stage IIIB Melanoma
Primary: Best Overall Response Rate (BORR) — 2; 17; 1 Participants
Phase 2 N=132 A Study of Vemurafenib in Previously Treated Patients With Metastatic Melanoma
Malignant Melanoma
Primary: Best Overall Response (BOR) Assessed by an Independent Review Committee Using Response Evaluation Criteria In Solid Tumors (RECIST 1.1) — 52.3 Percentage of participants
Phase 2 N=51 A Study of Vemurafenib (RO5185426) in Participants With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation
Neoplasms
Primary: Best Overall Response Rate in TKI-Naive Participants — 42.3 percentage of participants
Phase 3 N=402 Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
Metastatic or Unresectable Cutaneous Melanoma
Primary: Progression-Free Survival (PFS) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 — 2.83; 1.51 Months — p=< 0.001
Phase 3 N=675 A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)
Malignant Melanoma
Primary: Overall Survival — 43; 75; 293; 261 participants — p=<0.0001
Phase 3 N=250 A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
Cancer
Primary: Progression-free Survival (PFS) as Assessed by the Investigator — 6.9; 2.7 Months — p=<0.0001
Phase 2 N=91 Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients
Melanoma
Primary: Overall Survival — 424; 321 Days — p=0.3873
Phase 3 N=423 A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Melanoma
Primary: Progression-Free Survival (PFS) as Assessed by the Investigator — 10.2; 8.8 Months
Phase 2 N=77 Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma
Cancer · Melanoma
Primary: Objective Response Rate (ORR) — 61 Percentage of Participants
Phase 2 N=23 An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor
Melanoma
Primary: Overall Response Rate (ORR) — 10 Percentage of Participants
Phase 2 N=177 Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.
Cancer
Primary: Overall Response Rate (ORR) — 27; 39; 23; 4 Participants
Phase 2 N=125 Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain
Melanoma and Brain Metastases
Primary: Intracranial Response (IR) Rate in Cohort A — 45 Number of participants — p=<.0001
Phase 3 N=921 Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma
Melanoma
Primary: Part 1: Progression Free Survival (PFS) by BIRC in Combo 450 Group as Compared to Vemurafenib Group — 14.9; 7.3 Months
Phase 3 N=514 A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma
Melanoma
Primary: Progression-Free Survival (PFS), as Determined by Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 — 10.6; 15.1 months — p=0.0224
Phase 1 N=54 A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma
Melanoma and Metastatic Colorectal Cancer
Primary: Number of Participants With Dose-Limiting Toxicity (DLT) During Dose Escalation Phase — 0; 1; 0; 0 Participants